Engineered probiotic co‑expressing IL‑10 and Amuc_1100 modulates the gut‑brain axis to improve ASD‑like behaviors in BTBR mice
This study demonstrates that an engineered probiotic co-expressing IL-10 and Amuc_1100 alleviates ASD-like behaviors in BTBR mice by modulating the gut-brain axis through the reduction of intestinal inflammation, remodeling of the gut microbiota, and normalization of microglial function in the medial prefrontal cortex.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Autism spectrum disorder is a complex condition that affects how people connect with others and navigate the world. While the exact causes remain a puzzle, scientists have long suspected that the immune system plays a significant role. In many individuals with autism, the body's defense mechanisms appear to be in a state of constant, low-level alarm, leading to inflammation that can disrupt brain development and function. A key player in calming this internal fire is a natural protein called interleukin-10, or IL-10. This molecule acts as a peacekeeper, telling the immune system to stand down and reducing harmful inflammation. However, in some cases of autism, the body does not produce enough of this calming signal, or it cannot deliver it effectively to the right places. Traditional medicine struggles here because giving the protein directly to a patient is difficult; it breaks down too quickly in the body and can cause unwanted side effects if it spreads everywhere at once.
This is where a new approach, detailed in recent research, offers a different path. Instead of injecting a drug, scientists have engineered a harmless, friendly bacterium to act as a tiny, living factory inside the gut. By placing this modified microbe into the digestive system, they hoped to create a steady, local supply of the calming IL-10 protein right where it is needed most. The study focused on a specific strain of mice that naturally displays behaviors similar to autism, such as avoiding social interaction and repeating the same movements over and over. The researchers wanted to see if feeding these mice their custom-made bacteria could quiet the immune system, calm the brain, and change how the mice behaved.
The team used a well-known, safe bacterium called Escherichia coli Nissle 1917, which has been used for decades to treat digestive issues in humans. They genetically tweaked this bacterium so that it would constantly produce two things: the mouse version of the IL-10 protein and a second protein called Amuc_1100, which comes from a different type of gut bacteria known for strengthening the intestinal barrier. This combination was designed to work together, with the second protein helping to seal the gut lining and the first protein soothing the immune system. The researchers then gave this engineered bacteria to the autistic-like mice every day for four weeks, while a control group received a version of the bacteria that did not produce these proteins.
The results were striking. After the month-long treatment, the mice that received the engineered bacteria showed a dramatic improvement in their social behavior. In a test where they could choose to spend time near another mouse or an empty object, the treated mice clearly preferred the company of the other mouse, whereas the untreated mice showed no such interest. The treatment also reduced the repetitive behaviors that are common in the model; the mice groomed themselves less and buried fewer marbles in their bedding, actions that are often seen as signs of anxiety or compulsion in these animals. These changes suggested that the treatment was not just making the mice feel better physically, but was actually altering the core traits associated with their condition.
To understand how this happened, the scientists looked inside the mice's bodies. They found that the treatment successfully reduced inflammation in the intestines. The lining of the gut, which had been damaged and disorganized in the untreated mice, looked healthy and structured again. Levels of a marker for gut inflammation dropped significantly, returning to normal ranges. Furthermore, the treatment reshaped the community of microbes living in the gut. It encouraged the growth of beneficial bacteria that help maintain a healthy gut environment while suppressing the types of bacteria linked to inflammation. This suggests that the engineered bacteria did not just act alone; they helped restore a balanced ecosystem within the digestive tract, which is known to communicate closely with the brain.
The changes did not stop at the gut. When the researchers examined the brains of the treated mice, specifically in a region called the medial prefrontal cortex that is crucial for social behavior, they found that the signs of inflammation had quieted down. The brain tissue showed lower levels of genes that drive inflammation, particularly those involved in a pathway known as IL-17 signaling, which is often overactive in autism. Perhaps most importantly, the study looked at the brain's immune cells, called microglia. In the untreated mice, these cells were in a state of high alert, constantly scanning for threats and even eating away at healthy connections between brain cells. In the treated mice, these cells shifted back to a calm, protective state. They stopped their excessive cleaning of brain connections and began to support the brain's normal function instead.
The study provides a clear proof of concept that delivering a calming immune signal directly through the gut can have a ripple effect, reaching all the way to the brain to improve behavior. By using a living bacterium to produce the necessary protein locally, the researchers bypassed the problems of short-lived drugs and systemic toxicity. While this work was done in mice and more research is needed to ensure safety and effectiveness in humans, it points to a promising new strategy. It suggests that for some forms of autism driven by immune imbalance, the answer might lie not in a pill or a shot, but in a gentle, sustained conversation between the gut and the brain, mediated by a tiny, engineered helper.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.